相关实验视频

Updated: Apr 18, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

针对PD-L1-阴性肺腺癌的第一线治疗选择:现实世界的分析

Lijuan Chen^1,2, Jie Liu^1,2, Junfeng Lu^1,2

¹Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Frontiers in oncology

|June 19, 2025

概括

对肺腺癌患者来说,对于编程死亡连接体1 (PD-L1) 和常见的基因变异来说,贝瓦齐祖马布加化疗提供了优越的整体存活率和疾病控制,与单独的化疗或免疫疗法相比.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

对于对编程死亡连接体1 (PD-L1) 和常见基因变异阴性患者的肺腺癌 (LUAD) 治疗仍然是一个挑战.
确定最佳的第一线疗法对于改善这种特定的LUAD亚组患者的治疗结果至关重要.

研究的目的:

评估和比较PD-L1-阴性LUAD患者缺乏常见基因变异的不同一线治疗方案的临床有效性和安全性.
为了确定这个患者群体的最佳治疗策略.

主要方法:

一项比较性研究包括159名PD-L1-阴性LUAD患者,没有常见的基因变异.
患者接受了化疗 (A组),免疫疗法-化疗 (B组) 或贝瓦西祖马布加化疗 (C组).
分析了临床有效性 (PFS,OS,DCR) 和安全性 (AE).

主要成果:

与单独化学疗法 (A组) 和免疫疗法-化学疗法 (B组) 相比,贝瓦西祖马布加化学疗法 (C组) 显示的整体存活时间 (OS) 显著更长.
与A组相比,B组和C组的无进展生存 (PFS) 显著改善.
组C显示出优异的疾病控制率 (DCR),可管理的3-4级不良事件在所有组中都是可比的.

结论:

建议贝瓦西祖马布加化疗作为PD-L1-阴性LUAD患者的优先一线治疗,没有常见的驱动基因改变.
这种方案提供了更好的生存效益和疾病控制,支持个性化治疗策略.

关键词:

PD-L1 负数没有这是bevacizumab的治疗方法.作为一线的治疗方法.免疫疗法免疫疗法肺部腺癌的癌症预后预后预后

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...